Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Transgenic GroupTSE:2342 -2.37%61 PB Ratio is 0.72 as of Jul. 29, 2026, which is 50% below its 10-year median of 1.44. GuruFocus rates TSE:2342 with a GF Score™ of 61/100 and a GF Value™ of 円258.37 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,227 Biotechnology companies, Transgenic Group ranks better than 87.78% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-29), Transgenic Group's share price is 円206.00. Transgenic Group's Book Value per Share for the quarter that ended in Mar. 2026 was 円287.05. Hence, Transgenic Group's PB Ratio of today is 0.72.
Good Sign:
Transgenic Group Inc stock PB Ratio (=0.74) is close to 1-year low of 0.68.
The historical rank and industry rank for Transgenic Group's PB Ratio or its related term are showing as below:
TSE:2342'
s PB Ratio Range Over the Past 10 Years
Min: 0.49 Med: 1.44 Max: 3.58
Current: 0.72
During the past 13 years, Transgenic Group's highest PB Ratio was 3.58. The lowest was 0.49. And the median was 1.44.
TSE:2342's PB Ratio is ranked better than 87.78% of 1227
companies
in the Biotechnology industry
Industry Median: 2.75
vs TSE:2342: 0.72
During the past 12 months, Transgenic Group's average Book Value Per Share Growth Rate was 0.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -2.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 3.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Transgenic Group was 12.00% per year. The lowest was -9.70% per year. And the median was 4.45% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Transgenic Group PB Ratio Related Terms
Transgenic Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Transgenic Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Transgenic Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgenic Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgenic Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Transgenic Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Transgenic Group (TSE:2342) has a PB Ratio of 0.72 as of Jul. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Transgenic Group and its competitors. This is 50% below median its historical median of 1.44. Over the past decade, Transgenic Group's PB Ratio has ranged from 0.49 to 3.58. According to the industry distribution chart, Transgenic Group ranks #150 out of 1227 companies in the Biotechnology industry, placing it in the top 12.2%.
Is Transgenic Group's PB Ratio too high?
Transgenic Group's current PB Ratio of 0.72 is 50% below median its 10-year median of 1.44. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 3.58. The Biotechnology industry median PB Ratio is 2.75. Transgenic Group's value of 0.72 is 73.8% below this industry median. Based on the distribution chart, Transgenic Group ranks #150 out of 1227 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Transgenic Group has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgenic Group ranks #150 out of 1227 companies for PB Ratio. This places Transgenic Group in the top 12% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.75. Transgenic Group's value of 0.72 is 73.8% below this benchmark. Historically, Transgenic Group's own PB Ratio has ranged from 0.49 to 3.58 over the past decade. While the company's 10-year median is 1.44 vs. the industry median of 2.75, Transgenic Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.75, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transgenic Group's current PB Ratio of 0.72 is 73.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Transgenic Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transgenic Group's current PB Ratio is 0.72, which is 50% below median its own 10-year median of 1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円258.37, compared to a current price of 円206.00 — trading 20.3% below its estimated fair value. The current PB Ratio is 0.72, which is 50% below median its 10-year median of 1.44 and 73.8% below the Biotechnology industry median of 2.75. Transgenic Group's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current PB Ratio is 0.72 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgenic Group (TSE:2342) Overvalued in 2026?
Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued.
The current stock price of 円206.00 is trading 20.3% below its estimated GF Value™ of 円258.37.
GuruFocus considers Transgenic Group to be Modestly Undervalued.
Key valuation signals for TSE:2342:
PB Ratio: 0.72 (50% below median its 10-year median of 1.44)
GF Value™: 円258.37 vs. price of 円206.00 (20.3% below fair value)
Industry Position: 73.8% below the Biotechnology median (#150 of 1227)
No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
61GF Score
Get the complete analysis for TSE:2342
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2342 has been successfully added to your 
